Education
About Us
Working with TipRanks
Follow Us
Fluicell AB (DE:5J90)
FRANKFURT:5J90
5J90 Stock Chart & Stats
€1.29
--
Market closed
€1.29
--
Day’s Range― - ―
52-Week Range€0.67 - €2.04
Previous CloseN/A
VolumeN/A
Average Volume (3M)94.00
Market Cap
€1.68M
Enterprise Value€15.60M
Total Cash (Recent Filing)€2.26M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta24.54
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,373,703
10 Day Avg. Volume182
30 Day Avg. Volume94
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero-debt Balance SheetA zero-debt capital structure materially lowers refinancing and interest risk, preserving financial optionality. Over the next several months this durability reduces default risk, gives management flexibility to prioritize product investment or strategic fundraising, and eases cash runway pressure versus leveraged peers.
Strong Recent Revenue ReboundA ~124% TTM revenue rebound signals improving commercial traction and product-market fit for instruments and consumables. If sustained, this supports scaling, operating leverage, and margin recovery over 2–6 months, strengthening prospects for eventual profitability as fixed costs are spread across higher sales.
Consumables-driven Product ModelA platform combining instruments with recurring consumables creates durable revenue visibility and customer stickiness. For academic and industrial labs this model fosters repeat purchases and higher lifetime value, supporting sustainable revenue growth and a defendable competitive position in single-cell workflows.
Bears Say
Ongoing Cash BurnPersistent negative operating and free cash flows indicate the business cannot self-fund growth and will likely need external capital within months. This cash burn increases dilution and execution risk, constrains discretionary R&D and commercial spending, and limits the company’s ability to scale sustainably.
Deep Losses Eroding EquityDeclining shareholders' equity alongside TTM net losses reflects capital erosion that weakens the balance sheet. Over the medium term this raises the probability of further dilution, reduces financial resilience to shocks, and hampers credibility with partners and customers for larger commercial engagements.
Very Small Organizational ScaleA tiny headcount limits sales coverage, service capacity, and parallel R&D initiatives, increasing execution risk as the company scales. Competing with larger instrument vendors and servicing industrial lab clients may require rapid hiring or partnerships, making near-term growth and operational consistency harder to sustain.
5J90 FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was €0.67 and its highest was €2.04 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is €1.68M.
When is Fluicell AB’s upcoming earnings report date?
Fluicell AB’s upcoming earnings report date is May 08, 2026 which is in 72 days.
How were Fluicell AB’s earnings last quarter?
Fluicell AB released its earnings results on Feb 20, 2026. The company reported €0.007 earnings per share for the quarter, beating the consensus estimate of N/A by €0.007.
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Fluicell AB reported an EPS of €0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 28.409%.
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in DE:5J90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fluicell AB
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.